Business Context and Reporting Period
This Form 8-K was filed by MacroGenics, Inc. on February 25, 2025. The report addresses Item 5.02 regarding the departure of directors or certain officers and compensatory arrangements. Specifically, it details an amendment to the separation and consulting agreement between the Company and Dr. Scott Koenig, its President and Chief Executive Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the amendment to Dr. Koenig's separation agreement, originally dated October 25, 2024. Key modifications include:
- Extended Separation Date: The original separation date of February 28, 2025, has been extended to a date to be determined by the Board of Directors, subject to fourteen days' notice to Dr. Koenig.
- Extended Advisory Services: The termination date for Dr. Koenig's advisory services has been extended from February 28, 2030, to the fifth anniversary of the new Separation Date.
- Compensation Adjustment: Dr. Koenig will receive a prorated target 2025 annual bonus, payable in the first payroll run occurring on or after the Separation Date.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Board of Directors is currently conducting a special executive search to identify the next Chief Executive Officer. The Board expects this process to conclude over the coming weeks. The extension of Dr. Koenig's role is intended to support the transition during this search.
Risks and Contingencies: The filing includes standard forward-looking statements regarding the timing of the executive search. Actual results may differ materially due to risks and uncertainties described in the Company's "Risk Factors" section in other SEC filings. The Company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the exact date of Dr. Koenig's final separation once determined by the Board.
- Review the full text of the Amendment to the Separation Agreement when filed in the Form 10-K for the year ended December 31, 2024.
- Monitor announcements regarding the appointment of the new Chief Executive Officer.
- Confirm the specific calculation and payout timing of the prorated 2025 annual bonus.